Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: A survey

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 731-739

  Nordmann, Jean Philippe ^a   Baudouin, Christophe ^a   Renard, Jean Paul ^b   Denis, Philippe ^c   Lafuma, Antoine ^d   Laurendeau, Caroline ^d   Jeanbat, Viviane ^d   Berdeaux, Gilles ^e,f  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b University of Paris Descartes   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CEMKA EVAL   (France)

^e Alcon France   (France)

^f University of Paris Cité   (France)

Author keywords

Compliance; Efficacy; Glaucoma; Intraocular pressure control

Indexed keywords

EYE DROPS; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

AGE; AGED; ARTICLE; CATARACT; COMORBIDITY; COMPUTER SYSTEM; COMPUTERIZED BOTTLE HOLDER; DIABETIC RETINOPATHY; DRUG DOSE REGIMEN; DRUG INSTILLATION; FEMALE; GENDER BIAS; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; REMINDER SYSTEM; RETINA DETACHMENT; RISK FACTOR; UVEITIS;

EID: 77956126075     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: None     Document Type: Article

References (40)

1. Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology. 2001;108:1966-1972.
2. Mitchell P, Smith W, Attebo K, et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains eye study. Ophthalmology. 1996;103:1661-1669.
3. Klein BEK, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992;99:1499-1504.
4. Rudnicka AR, Mt-Isa S, Owen CG, et al. Variations in primary openangle glaucoma prevalence by age, gender, and race: a Bayesian metaanalysis. Invest Ophthalmol Vis Sci. 2006;47:4254-4261.
5. Bron A, Baudouin C, Nordmann JP, et al. [Prevalence of intraocular hypertension and glaucoma in a nonselected French population]. J Fr Ophtalmol. 2006;29:635-641. French.
6. Nizankowska MH, Kaczmarek R. Prevalence of glaucoma in the Wroclaw population. The Wroclaw Epidemiological Study. Ophthalmic Epidemiol. 2005;12:363-371.
7. Antón A, Andrada MT, Mujica V, et al. Prevalence of primary open- angle glaucoma in a Spanish population: the Segovia Study. J Glaucoma. 2004;13:371-376.
8. Broman AT, Quigley HA. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:253-254.
9. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary openangle glaucoma. Arch Ophthalmol. 2002;120:701-713.
10. McKinnon SJ, Goldberg LD, Peeples P, et al. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008; 14(Suppl 1):S20-S27.
11. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England and Wales. BMC Public Health. 2006;6:58.
12. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880-2883.
13. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052-5057.
14. Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology. 2007;114: 1599-1606.
15. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-606.
16. Bour T, Blanchard F, Segal A. [Therapeutic observance and life of patients with primary open-angle glaucoma. Apropos of 341 cases in the department of Marne]. J Fr Ophtalmol. 1993;16:380-391. French.
17. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233-236.
18. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol. 2006;141(Suppl 1): S28-S33.
19. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116(2):191-199.
20. Cronin TH, Kahook MY, Lathrop KL, Noecker RJ. Accuracy and performance of a commercially available dosing aid. Br J Ophthalmol. 2007;91(4):497-499.
21. Friedman DS, Jampel HD, Congdon NG, Miller R, Quigley HA. The tarvatan dosing aid accurately records when drops are taken. Am J Ophthalmol. 2007;143(4):699-701.
22. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477-480.
23. Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy a randomized controlled trial. Ophthalmology. Epub 2010 Apr 10.
24. Freedman J. What is new after 40 years of glaucoma implants. J Glaucoma. Epub 2010 Feb 22.
25. Papaconstantinou D, Georgalas I, Karmiris E, et al. Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study. Acta Ophthalmol. 2010;88(1):80-85.
26. Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000;14:752-756.
27. Forsman E, Kivelä T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma. 2007;16:313-319.
28. Flowers B, Wand M, Piltz-Seymour J, et al; and the Travatan Dosing Aid Study Group. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28:1803-1811.
29. Kass MA, Meltzer DW, Gordon M. A miniature compliance monitor for eyedrop medication. Arch Ophthalmol. 1984;102:1550-1554.
30. ® Dosing Aid. http://www.alcon.com/en/professionals/product-advances.asp
31. Directive 2001/20/EC of the European parliament and of the council of 2001 Apr 4. http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=en&numdoc=32001L0020&model=guicheti
32. Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé. http://www.enseignementsuprecherche.gouv.fr/cid20537/cctirs.html
33. La commission nationale de l'informatique et des libertés http://www.cnil.fr/
34. Lebart L, Morineau A, Warwick KM. Multivariate descriptive statistical analysis: correspondence analysis and related techniques for large matrices. New York: John Willey & Sons. 1984.
35. Anderberg MR. Cluster analysis for applications. New York: Academic Press. 1973.
36. Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454-461.
37. Traverso CE, Walt JG, Stern LS, Dolgitser M. Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2009;25:77-82.
38. Pappa C, Hyphantis T, Pappa S, et al. Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment. J Psychosom Res. 2006;61:609-617.
39. Regnault A, Viala-Danten M, Gilet H, Berdeaux G. Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment. BMC Ophthalmol. 2010;10:1.
40. Nordmann JP, Denis P, Vigneux M, Trudeau E, Guillemin I, Berdeaux G. Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ) in glaucoma using a qualitative study. BMC Health Serv Res. 2007;7:124.